B. Riley Wealth Advisors Inc. Sells 408 Shares of IQVIA Holdings Inc. (NYSE:IQV)

B. Riley Wealth Advisors Inc. lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 12.8% in the 3rd quarter, Holdings Channel.com reports. The firm owned 2,786 shares of the medical research company’s stock after selling 408 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in IQVIA were worth $653,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in IQV. Oddo BHF Asset Management Sas bought a new stake in shares of IQVIA in the third quarter valued at approximately $2,771,000. Franklin Resources Inc. raised its stake in IQVIA by 1.2% during the 3rd quarter. Franklin Resources Inc. now owns 501,807 shares of the medical research company’s stock valued at $117,031,000 after purchasing an additional 6,011 shares during the last quarter. Tidal Investments LLC boosted its holdings in IQVIA by 9.3% in the 3rd quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company’s stock valued at $1,417,000 after purchasing an additional 509 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in IQVIA in the 3rd quarter worth $2,310,000. Finally, Arvest Bank Trust Division acquired a new position in shares of IQVIA during the third quarter valued at about $21,079,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 2.9 %

Shares of IQV opened at $190.97 on Thursday. The company has a market capitalization of $34.66 billion, a P/E ratio of 25.06, a PEG ratio of 2.05 and a beta of 1.49. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The business’s 50 day simple moving average is $210.32 and its 200-day simple moving average is $223.64. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on IQV shares. Redburn Atlantic initiated coverage on IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 target price on the stock. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Robert W. Baird cut their target price on IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a research note on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $256.19.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.